GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quantrx Biomedical Corp (OTCPK:QTXB) » Definitions » Return-on-Tangible-Equity

Quantrx Biomedical (Quantrx Biomedical) Return-on-Tangible-Equity : 0.00% (As of Sep. 2022)


View and export this data going back to . Start your Free Trial

What is Quantrx Biomedical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Quantrx Biomedical's annualized net income for the quarter that ended in Sep. 2022 was $-0.24 Mil. Quantrx Biomedical's average shareholder tangible equity for the quarter that ended in Sep. 2022 was $-2.81 Mil. Therefore, Quantrx Biomedical's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2022 was N/A%.

The historical rank and industry rank for Quantrx Biomedical's Return-on-Tangible-Equity or its related term are showing as below:

QTXB's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.395
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Quantrx Biomedical Return-on-Tangible-Equity Historical Data

The historical data trend for Quantrx Biomedical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantrx Biomedical Return-on-Tangible-Equity Chart

Quantrx Biomedical Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity - - - -

Quantrx Biomedical Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Quantrx Biomedical's Return-on-Tangible-Equity

For the Medical Instruments & Supplies subindustry, Quantrx Biomedical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quantrx Biomedical's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quantrx Biomedical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Quantrx Biomedical's Return-on-Tangible-Equity falls into.



Quantrx Biomedical Return-on-Tangible-Equity Calculation

Quantrx Biomedical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2021 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=-0.26/( (-2.381+-2.641 )/ 2 )
=-0.26/-2.511
=N/A %

Quantrx Biomedical's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2022 )  (Q: Jun. 2022 )(Q: Sep. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2022 )  (Q: Jun. 2022 )(Q: Sep. 2022 )
=-0.244/( (-2.779+-2.841)/ 2 )
=-0.244/-2.81
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2022) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Quantrx Biomedical  (OTCPK:QTXB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Quantrx Biomedical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Quantrx Biomedical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantrx Biomedical (Quantrx Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
10190 SW 90th Avenue, Tualatin, OR, USA, 97062
Quantrx Biomedical Corp operates towards the development and commercialization of patented mini form pad (PAD) based products. The PAD products are based on the company's non-woven disposable absorbent pad technology and it is involved in the PAD-based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its platforms include inSync(R), Unique(TM), and OEM branded over-the-counter and laboratory testing products.
Executives
Michael S Abrams director 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Robert G. Pinco director 1700 K STREET NW, SUITE 300, WASHINGTON DC 20006
Hayes Arthur H Jr director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Matthew Balk 10 percent owner 229 WEST 60TH STREET, NEW YORK NY 10023
Evan Levine director, 10 percent owner 1517 SAN JACINTO ST., HOUSTON TX 77002
Hayes Arthur Hull Jr director C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901
Cindy Horton officer: V.P. of Diagnostics 209 BRITTANY PARK, ANDERSON SC 29621
Sasha Afanassiev officer: Officer 120 GARRISON COURT, LANGHORNE PA 19047
Shalom Hirschman officer: Officer 5240 BLACKSTONE AVENUE, RIVERDALE NY 10471
William H Fleming director, officer: Secretary
Walter W Witoshkin director, officer: President and CEO 321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002
Mark Capital Llc 10 percent owner 5173 SEAGROVE PLACE, SAN DIEGO CA 92130
Sherbrooke Partners, Llc 10 percent owner 570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282

Quantrx Biomedical (Quantrx Biomedical) Headlines

No Headlines